investor.stemcellsinc.com

StemCells, Inc. - Investor Relations - Investor Home

Follow StemCells, Inc. on Twitter. Keep up with StemCells, Inc. on LinkedIn. What Sets Us Apart. The Promise of Stem Cells. Spinal Cord Injury (SCI). Age-related Macular Degeneration (AMD). Neuronal Ceroid Lipofuscinosis (NCL). Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability. Learn more about What Sets Us Apart. Replication or redistribution...

http://investor.stemcellsinc.com/

OVERVIEW OF investor.stemcellsinc.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

0

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.STEMCELLSINC.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

May

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Thursday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.3 out of 5 with 8 reviews

5 star

2

4 star

6

3 star

0

2 star

0

1 star

0

Hey there! Start your review of investor.stemcellsinc.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

CONTACTS AT INVESTOR.STEMCELLSINC.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

0

SSL

EXTERNAL LINKS

23

SITE IP

184.51.0.249

LOAD TIME

0 sec

SCORE

6.2

PAGE TITLE

StemCells, Inc. - Investor Relations - Investor Home | investor.stemcellsinc.com Reviews

<META> DESCRIPTION

Follow StemCells, Inc. on Twitter. Keep up with StemCells, Inc. on LinkedIn. What Sets Us Apart. The Promise of Stem Cells. Spinal Cord Injury (SCI). Age-related Macular Degeneration (AMD). Neuronal Ceroid Lipofuscinosis (NCL). Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability. Learn more about What Sets Us Apart. Replication or redistribution...

<META> KEYWORDS

1 investor relations

2 groundbreaking science

3 breakthrough medicine

4 about us

5 overview

6 business strategy

7 ceo corner

8 people

9 careers

10 science

CONTENT

Page content here

KEYWORDS ON PAGE

investor relations,groundbreaking science,breakthrough medicine,about us,overview,business strategy,ceo corner,people,careers,science,our pre clinical studies,publications,intellectual property,licensees,research collaborations,resources / links,hucns sc

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

StemCells, Inc. - Investor Relations - Investor Home | investor.stemcellsinc.com Reviews

https://investor.stemcellsinc.com

Follow StemCells, Inc. on Twitter. Keep up with StemCells, Inc. on LinkedIn. What Sets Us Apart. The Promise of Stem Cells. Spinal Cord Injury (SCI). Age-related Macular Degeneration (AMD). Neuronal Ceroid Lipofuscinosis (NCL). Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability. Learn more about What Sets Us Apart. Replication or redistribution...

LINKS TO THIS WEBSITE

stemcellsinc.com

StemCells, Inc. - Science

http://www.stemcellsinc.com/Science/Overview

The Promise of Stem Cells. An unwavering commitment to rigorous science. Characterizes our culture, guiding our scientific and clinical integrity as well as our business principles. Credited with an impressive record of discoveries and firsts, the StemCells, Inc. team has a distinguished heritage of scientific achievement in stem cell biology. Our science is driven by. Work is never progressed without substantiation from. Learn more about our pre-clinical studies…. Learn more about stem cells…. Imaginati...

stemcellsinc.com

StemCells, Inc. - Pre-Clinical Studies: Lysosomal Storage Disorders

http://www.stemcellsinc.com/Science/Pre-Clinical-Studies/Lysosomal-Storage-Disorders

The Promise of Stem Cells. Lysosomal Storage Disorders / NCL: Pre-clinical Studies. Published pre-clinical data demonstrates the therapeutic potential of the StemCells HuCNS-SC. Purified human neural stem cells) platform technology to treat neurodegenerative diseases such as neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disorder also known as Batten disease. Download PDF of published research; see page 316, Figure 6…. Absence of neurons in control group. Time on Rotorod (seconds). Findings fr...

stemcellsinc.com

StemCells, Inc. - Science: Publications

http://www.stemcellsinc.com/Science/Publications

The Promise of Stem Cells. The following is a select list of peer-reviewed publications and poster presentations associated with StemCells, Inc. therapeutic product development programs. These publications can also be accessed online at PubMed.gov. Publications marked with an asterisk (*) are available on PubMed.gov as abstract only. Overview of Clinical Translation. Tsukamoto, A., Uchida, N., Capela, A., Gorba, T., Huhn, S., Clinical translation of human neural stem cells. Stem Cell Research and Therapy.

stemcellsinc.com

StemCells, Inc. - News & Events

http://www.stemcellsinc.com/News-Events/Highlights

Is the great promise of stem cell therapeutics to treat, and possibly cure, a broad range of human diseases. Follow our progress as we work to make this vision a reality. Upcoming or Recent Events. 3rd Annual Growth Capital Expo MicroCap Investor Conference. Las Vegas, NV. May 4, 2016, 11:00 AM PDT,. GTC Stem Cell Summit. April 25, 2016. American Spinal Injury Association 2016 Annual Meeting. April 14-16, 2016. Martin McGlynn and Stephen Huhn Interviewed on BioTech Nation Radio Podcast. What Sets Us Apart.

stemcellsinc.com

StemCells, Inc. - Pre-Clinical Studies: Alzheimer’s and Stroke

http://www.stemcellsinc.com/Science/Pre-Clinical-Studies/Alzheimers-Stroke

The Promise of Stem Cells. Alzheimer’s Disease and Stroke: Pre-clinical Studies. We believe that our HuCNS-SC. Human neural stem cells have the potential to enhance cellular function associated with a broad range of neurological conditions, such as Alzheimer’s disease and stroke. We have conducted research studies to evaluate the feasibility and utility of our human neural stem cells as a potential treatment for these indications. About Alzheimer’s Disease. View our publications on Stroke…. Neuronal Cero...

stemcellsinc.com

StemCells, Inc. - Science: The Promise of Stem Cells

http://www.stemcellsinc.com/Science/The-Promise-of-Stem-Cells

The Promise of Stem Cells. Nobuko Uchida, PhD. The Promise of Stem Cells. Because of the self-renewal property of stem cells, a single transplantation treatment may have the potential to return an impaired organ to proper function for the life of the patient. The concept of cell-based therapy (or simply cell therapy, as it is sometimes called) is to repair, replace or supplement damaged or diseased cells with healthy cells. The fact is, we have much to learn from stem cells. Nobuko Uchida, PhD. It’s an i...

stemcellsinc.com

StemCells, Inc. - Clinical Programs: Our Clinical Approach

http://www.stemcellsinc.com/Clinical-Programs/AMD

Spinal Cord Injury (SCI). Age-related Macular Degeneration (AMD). Neuronal Ceroid Lipofuscinosis (NCL). Age-related Macular Degeneration (AMD): Clinical Program. Phase II Clinical Trial in GA-AMD. Suspended pending funding TBD). Based upon both the strength of our pre-clinical studies and the positive results from our Phase I/II clinical trial, StemCells, Inc. has initiated the Radiant. A Phase II proof-of-concept study using our HuCNS-SC. Phase I/II Trial in GA-AMD. Top-line results for the Phase I/II c...

stemcellsinc.com

StemCells, Inc. - Clinical Programs: Our Clinical Approach

http://www.stemcellsinc.com/Clinical-Programs/SCI

Spinal Cord Injury (SCI). Age-related Macular Degeneration (AMD). Neuronal Ceroid Lipofuscinosis (NCL). Spinal Cord Injury: Clinical Program. Phase II Trial in Cervical Spinal Cord Injury (SCI). Learn more about the six-month interim results from Cohort 1 of the Pathway Study…. Learn more about ongoing enrollment in the Pathway Study…. Phase I/II Trial in Thoracic SCI. Enrollment in this study, which transplanted patients with T2-T11 thoracic spinal cord injury, was completed in May 2014. Top-line re...

stemcellsinc.com

StemCells, Inc. - Clinical Programs: Our Clinical Approach

http://www.stemcellsinc.com/Clinical-Programs/Manufacturing

Spinal Cord Injury (SCI). Age-related Macular Degeneration (AMD). Neuronal Ceroid Lipofuscinosis (NCL). Stem Cells in a Bottle. Expandable and bankable, HuCNS-SC cells can ultimately be “manufactured” at commercial-scale as “stem cells in a bottle,” then distributed for patient doses, much like an off-the-shelf pharmaceutical product for on-demand use. StemCells has pioneered innovative manufacturing methodologies in order to supply our therapeutic clinical development programs with HuCNS-SC.

stemcellsinc.com

StemCells, Inc. - Pre-Clinical Studies: Myelination Disorders

http://www.stemcellsinc.com/Science/Pre-Clinical-Studies/Myelin-Disorders

The Promise of Stem Cells. Myelination Disorders / PMD: Pre‑clinical Studies. Published pre-clinical data demonstrates the therapeutic potential of the StemCells HuCNS-SC. Purified human neural stem cells) platform technology to treat myelination disorders such as Pelizaeus-Merzbacher disease (PMD). Pre-clinical Proof of Concept. Download PDF of published research; see page 7, Figure 6…. Learn about our completed PMD clinical trials…. View our publications on myelination disorders…. Findings from studies...

UPGRADE TO PREMIUM TO VIEW 13 MORE

TOTAL LINKS TO THIS WEBSITE

23

SOCIAL ENGAGEMENT

stemcellsinc

OTHER SITES

investor.starbucks.com

Investor Overview | Investor Relations | Starbucks Coffee Company

Skip to Main Navigation. Skip to Main Content. Your bag is empty. Dividend and Stock Split History. Stock Quote and Stock Chart. 160;- 0.03. 08/07/15 4:00 pm ET. Minimum 15 minute delay. To inspire and nurture the human spirit one person, one cup and one neighborhood at a time. Starbucks Delivers Record Quarterly Revenue of $4.9 Billion and Record Q3 EPS. Starbucks Announces Additional Share Repurchase Authorization. Starbucks Announces Q3 FY15 Results Conference Call. Fiscal 2014 Annual Report.

investor.startek.com

Startek | Investor Relations Investor Overview

Q2 2015 StarTek Earnings Conference Call. 160;at 5:00 pm ET. Q2 2015 StarTek Earnings Conference Call. Monday, August 10, 2015 . 5:00 pm ET . Click here for webcast. Click here to add this event to your calendar. 160; 0.18. Data as of 08/07/15 3:59 pm ET. STARTEK Sets Second Quarter 2015 Conference Call for Monday, August 10, 2015 at 5:00 pm ET. STARTEK Completes Acquisition of ACCENT Marketing Services. STARTEK Reports First Quarter 2015 Results. Q2 2015 StarTek Earnings Conference Call.

investor.stateauto.com

State Auto Financial Corporation

Skip to main content. Stock Quote and Chart. Annual Reports and Proxy Statements. State Auto Financial Corporation, headquartered in Columbus, Ohio, is a super regional property and casualty insurance holding company and is proud to be a Trusted Choice. Company partner. STFC stock is traded on the NASDAQ Global Select Market. State Auto Names Suzanne Sinclair Chief People Officer. Dec 07, 2016. There are currently no events scheduled. Dec 08, 2016. Learn about doing business with State Auto.

investor.steadfast.com.au

Steadfast Investor Centre

Why invest in Steadfast.

investor.steelexcel.com

Steel Excel Inc. - Investor Relations

RAID Controllers and HBAs. RAID Silicon and Software. Managed Hosting and Corporate IT. SSD Cache Performance Kit. Public and Investor Relations. James F. McCabe, Jr. 160; 0.65. Data as of 07/06/15 2:47 pm ET. Minimum 20 minute delay. Steel Excel Inc. Reports 2015 Second Quarter Financial Results. Steel Excel Inc. Reports 2015 First Quarter Financial Results. Steel Excel Inc. Reports 2014 Fourth Quarter Financial Results. Steel Excel Inc. Reports 2014 Third Quarter Financial Results. Historical and curre...

investor.stemcellsinc.com

StemCells, Inc. - Investor Relations - Investor Home

Follow StemCells, Inc. on Twitter. Keep up with StemCells, Inc. on LinkedIn. What Sets Us Apart. The Promise of Stem Cells. Spinal Cord Injury (SCI). Age-related Macular Degeneration (AMD). Neuronal Ceroid Lipofuscinosis (NCL). Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability. Learn more about What Sets Us Apart. Replication or redistribution...

investor.strathspeycrown.com

Strathspey Crown

Letter From The Chairman. Of Doctors, For Patients. We invite you to register now and gain access to the Strathspey Crown Confidential Investor Portal to learn more about our industry-leading business model and investment strategy.

investor.streamlinehealth.net

Investor Relations | Streamline Health Solutions

Skip to main navigation. Streamline Health Clinical Documentation Integrity (CDI). Streamline Health Computer Assisted Coding. Streamline Health Coding Audit Services. Streamline Health Accounts Receivable Management. Streamline Health Audit Management. Mission Vision and Values. Streamline Health Clinical Documentation Integrity (CDI). Streamline Health Computer Assisted Coding. Streamline Health Coding Audit Services. Streamline Health Accounts Receivable Management. Streamline Health Audit Management.

investor.strongcoir.com

Strongco Corporation - Investors

Vision, Mission and Values.

investor.suburbanpropane.com

About Suburban Propane - Investor Relations Home

Update on the situation in Anytown USA. 9:00 AM on Wednesday, July 22, 2009. The 2010 Common Unitholders Tri-Annual Meeting. Including a copy of our proxy statement). Become A New Customer. Company and Investor Information. Suburban Propane Partners, L.P. (NYSE:SPH) has been in the customer service business since 1928. A Master Limited Partnership since 1996, Suburban is a value-oriented company managed for long-term, consistent performance. 2015 Tri-Annual Meeting Results. 160;at 9:00 am ET. Replication...

investor.sucampo.com

Default Parallels Plesk Panel Page

Web Server's Default Page. This page is generated by Parallels Plesk Panel. The leading hosting automation software. You see this page because there is no Web site at this address. You can do the following:. Parallels is a worldwide leader in virtualization and automation software that optimizes computing for consumers, businesses, and Cloud services providers across all major hardware, operating systems, and virtualization platforms. To find out more information. Hypervisor Virtualization technology for.